5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study
    Meeting Abstract

    Smith, M. R.; Fizazi, K.; Sandhu, S. K.; Kelly, W. K.; Efstathiou, E.; Lara, P.; Yu, E. Y.; George, D. J.; Chi, K. N.; Saad, F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide
    Meeting Abstract

    Shore, N. D.; Efstathiou, E.; Patel, R.; Xu, R.; Johnson, A.; Multani, P. S.; Morris, M. J.; Abida, W.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT
    Meeting Abstract

    Pouliot, F.; Carroll, P.; Probst, S.; Pienta, K. J.; Rowe, S. P.; Saperstein, L.; Siegel, B.; Patnaik, A.; Preston, M. A.; Alva, A. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Flaig, T. W.; Friedlander, T. W.; Milowsky, M. I.; Srinivas, S.; Petrylak, D. P.; Merchan, J. R.; Bilen, M. A.; Carret, A. S.; Yuan, N.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab (MEDI4736) and tremelimumab in metastatic, nontransitional cell carcinoma of the urothelial tract
    Meeting Abstract

    Sarfaty, M.; Ostrovnaya, I.; Teo, M. Y.; Iyer, G.; Lee, C. H.; Peters, V.; Durocher, J.; Regazzi, A. M.; McCoy, A. S.; Hettich, G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase 0 study to assess [111In]-DOTA-h11B6 to target -human kallikrein-2 (hk2) in men with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; O'Donoghue, J. A.; Chetty, D.; Russell, M.; Zulch, E.; Avadhani, A. N.; Divgi, C. R.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Tykodi, S. S.; Escudier, B.; Oudard, S.; Hammers, H. J.; McDermott, D. F.; George, S.; Castellano, D.; Choueiri, T. K.; Alva, A. S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells
    Meeting Abstract

    Pan, W.; Zhang, Z.; Kimball, H.; Qiu, F.; Lee, G. S. M.; Choueiri, T. K.; Kantoff, P. W.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Single-arm, phase II study to evaluate the safety and efficacy of sacituzumab govitecan in patients with metastatic castration-resistant prostate cancer who have progressed on second generation AR-directed therapy
    Meeting Abstract

    Lang, J. M.; Kyriakopoulos, C.; Slovin, S. F.; Eickhoff, J. C.; Dehm, S.; Tagawa, S. T.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC)
    Meeting Abstract

    Lyou, Y.; Grivas, P.; Rosenberg, J. E.; Hoffman-Censits, J. H.; Quinn, D. I.; Petrylak, D. P.; Galsky, M. D.; Vaishampayan, U. N.; De Giorgi, U.; Gupta, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save